Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRI) Other Non-Current Liabilities: 2020-2024

Historic Other Non-Current Liabilities for Biofrontera (BFRI) over the last 5 years, with Dec 2024 value amounting to $1.2 million.

  • Biofrontera's Other Non-Current Liabilities fell 47.97% to $833,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $833,000, marking a year-over-year decrease of 47.97%. This contributed to the annual value of $1.2 million for FY2024, which is 70.31% down from last year.
  • As of FY2024, Biofrontera's Other Non-Current Liabilities stood at $1.2 million, which was down 70.31% from $4.2 million recorded in FY2023.
  • Biofrontera's 5-year Other Non-Current Liabilities high stood at $12.9 million for FY2021, and its period low was $62,000 during FY2020.
  • Over the past 3 years, Biofrontera's median Other Non-Current Liabilities value was $2.8 million (recorded in 2022), while the average stood at $2.8 million.
  • In the last 5 years, Biofrontera's Other Non-Current Liabilities spiked by 20,632.26% in 2021 and then tumbled by 77.88% in 2022.
  • Yearly analysis of 5 years shows Biofrontera's Other Non-Current Liabilities stood at $62,000 in 2020, then spiked by 20,632.26% to $12.9 million in 2021, then crashed by 77.88% to $2.8 million in 2022, then skyrocketed by 48.08% to $4.2 million in 2023, then tumbled by 70.31% to $1.2 million in 2024.